Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated HRAS

Radiation Research

Volumn 154, Issue 2, 2000, Pages 125-132

  Cohen Jonathan, Elizabeth ^a   Muschel, Ruth J ^a   McKenna, W Gillies ^a   Evans, Sydney M ^a   Cerniglia, George ^a   Mick, Rosemarie ^a   Kusewitt, Donna ^b   Sebti, Said M ^c   Hamilton, Andrew D ^d   Oliff, Allen ^e   Kohl, Nancy ^e   Gibbs, Jackson B ^e   Bernhard, Eric J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d YALE UNIVERSITY   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN FARNESYLTRANSFERASE INHIBITOR; RADIOSENSITIZING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; BLADDER TUMOR; CANCER RADIOTHERAPY; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; ONCOGENE H RAS; ONCOGENE RAS; PRIORITY JOURNAL; RADIOSENSITIVITY; RADIOSENSITIZATION; TUMOR XENOGRAFT;

ANIMALIA; MUS MUSCULUS;

EID: 17444454260     PISSN: 00337587     EISSN: None     Source Type: Journal    
DOI: 10.1667/0033-7587(2000)154[0125:FIPTAE]2.0.CO;2     Document Type: Conference Paper

References (46)

1. J. L. Bos, Ras oncogenes in human cancer: A review. Cancer Res. 49, 4682-4689 (1989).
2. T. J. FitzGerald, C. Daugherty, K. Kase, L. A. Rothstein, M. McKenna and J. S. Greenberger, Activated human N-ras oncogene enhances x-irradiation repair of mammalian cells in vitro less effectively at low dose rate. Am. J. Clin. Oncol. 8, 517-522 (1985).
3. M. D. Sklar, The ras oncogenes increase the intrinsic resistance of NIH 3T3 cells to ionizing radiation. Science 239, 645-647 (1988).
4. C. C. Ling and B. Endlich, Radioresistance induced by oncogenic transformation. Radiat. Res. 120, 267-279 (1989).
5. W. G. McKenna, M. C. Weiss, B. Endlich, C. C. Ling, V. J. Bakanauskas, M. L. Kelsten and R. J. Muschel, Synergistic effect of the v-myc oncogene with Hras on radioresistance. Cancer Res. 50, 97-102 (1990).
6. M. S. Mendonca, P. Boukamp, E. J. Stanbridge and J. L. Redpath, The radiosensilivity of human keratinocytes: Influence of activated c-H-ras oncogene expression and tumorigenicity. Int. J. Radiat Biol. 59, 1195-1206 (1991).
7. A. Hermens and P. Bentvelzen, Influence of the H-ras oncogene on radiation responses of a rat rhabdomyosarcoma cell line. Cancer Res. 52, 3073-3082 (1992).
8. ras isoprenylation. Int. J. Cancer 53, 302-307 (1993).
9. K. Pirollo, Y. Tong, Z. Villegas, Y. Chen and E. Chang, Oncogene-transformed NIH 3T3 cells display radiation resistance levels indicative of a signal transduction pathway leading to the radiation-resistant phenotype. Radiat. Res. 135, 234-243 (1993).
10. J. H. Jackson, C. G. Cockran, J. R. Bourne, P. A. Solski, J. E. Buss and C. Der, Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation. Proc. Natl. Acad. Sci. USA 87, 3042-3046 (1990).
11. F. L. Zhang and P. J. Casey, Protein prenylation: Molecular mechanisms and functional consequences. Annu. Rev. Biochem. 65, 241-269 (1996).
12. N. E. Kohl, S. D. Mosser, S. J. deSolms, E. A. Giuliani, D. L. Pompliano, S. L. Graham, R. L. Smith, E. M. Scolnick, A. Orliff and J. B. Gibbs, Selective inhibition of ras dependent transformation by a farnesyltransferase inhibitor. Science 260, 1934-1936 (1993).
13. G. L. James, J. L. Goldstein, M. S. Brown, T. E. Rawson, T. C. Somers, R. S. McDowell, C. W. Crowley, B. K. Lucas, A. D. Levinson and J. C. Marsters, Benzodiazepine peptidomimetics: Potent inhibitors of ras farnesylation in animal cells. Science 260, 1937-1942 (1993).
14. 1 block in p53 wild type tumor cells. J.Biol. Chem. 273, 20243-20251 (1998).
15. J. Sun, Y. Qian, A. D. Hamilton and S. M. Sebti, Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts. Oncogene 16, 1467-1473 (1998).
16. R. E. Barrington, M. A. Subler, E. Rands, C. A. Omer, P. J. Miller, J. E. Hundley, S. K. Koester, D. A. Troyer, D. J. Bearss and N. E. Kohl, A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. Mol. Cell. Biol. 18, 85-92 (1998).
17. N. Kohl, C. Omer, M. Connor, N. Anthony, J. Davide, S. deSolms, E. Giuliani, R. Gomez, S. Graham and A. Oliff, Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat. Med. 1, 792-797 (1995).
18. T. Nagasu, K. Yoshimatsu, C. Rowell, M. Lewis and A. Garcia, Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956. Cancer Res. 55, 5310-5314 (1995).
19. L. Sepp-Lorenzino, Z. Ma, E. Rands, N. E. Kohl, J. B. Gibbs, A. Oliff and N. Rosen, A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res. 55, 5302-5309 (1995).
20. A. Cox, A. Garcia, J. Westwick, J. Kowalczyk, M. Lewis, D. Brenner and C. Der, The CAAX peptidomimetic compound B581 specifically blocks farnesylated, but not geranylgeranylated or myristylated, oncogenic ras signaling and transformation. J. Biol. Chem. 269, 19203-19206 (1994).
21. P. F. Lebowitz, J. P. Davide and G. C. Prendergast, Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity. Mol. Cell. Biol. 15, 6613-6622 (1995).
22. G. Prendergast, J. Davide, S. deSolms, E. Giuliani, S. Graham, J. Gibbs, A. Oliff and N. Kohl, Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton. Mol. Cell. Biol. 14, 4193-4202 (1994).
23. P. F. Lebowitz, P. J. Casey, G. C. Prendergast and J. A. Thissen, Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB. J. Biol. Chem. 272, 15591-15594 (1997).
24. WAFI/CIPI/SDII in a p53-independent manner. J. Biol. Chem. 272, 27224-27229 (1997).
25. 2-M enrichment in A549 cells. Cancer Res. 57, 1846-1850 (1997).
26. E. J. Bernhard, G. Kao, A. D. Cox, S. M. Sebti, A. D. Hamilton, R. J. Muschel and W. G. McKenna, The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts. Cancer Res. 56, 1727-1730 (1996).
27. E. J. Bernhard, W. G. McKenna, A. D. Hamilton, S. M. Sebti, Y. Qian, J. Wu and R. J. Muschel, Inhibiting ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes. Cancer Res. 58, 1754-1761 (1998).
28. E. Lerner, Y. Qian, M. Blaskovich, R. D. Fossum, A. Vogt, J. Sun, A. Cox, C. Der, A. Hamilton and S. Sebti, Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic ras signalling by inducing cytoplasmic accumulation of inactive ras-raf complexes. J. Biol. Chem. 270, 26802-26806 (1995).
29. 2 delay and a hyperphosphorylation of p34CDC2 in HeLa cells. Cancer Res. 57, 1364-1370 (1997).
30. E. Cohen-Jonathan, C. Toulas, I. Ader, S. Monteil, C. Allal, J. Bonnet, A. D. Hamilton, S. M. Sebti, N. Daly-Schveitzer and G. Favre, The farnesyltransferase inhibitor FTI-277 suppresses the 24-kDa bFGF-induced radioresistance in HeLa cells expressing wild-type RAS. Radiat. Res. 152, 404-411 (1999).
31. S. Saito, M. Hata, R. Fukuyama, K. Sakai, J. Kudoh, H. Tazaki and N. Shimizu, Screening of H-ras gene point mutations in 50 cases of bladder carcinoma. Int. J. Urol. 4, 178-185 (1997).
32. P. Levesque, N. Ramchurren, K. Saini, A. Joyce, J. Libertino and I. C. Summerhayes, Screening of human bladder tumors and urine sediments for the presence of H-ras mutations. Int. J. Cancer 55, 785-790 (1993).
33. H. Namba, S. A. Rubin and J. A. Fagin, Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol. Endocrinol. 4, 1474-1479 (1990).
34. J. A. Anderson, J. C. Irish and B. Y. Ngan, Prevalence of RAS oncogene mutation in head and neck carcinomas. J. Otolaryncol. 21, 321-326 (1992).
35. W. Wilke, M. Maillet and R. Robinson, H-ras-1 point mutations in soft tissue sarcomas. Mod. Pathol. 6, 129-132 (1993).
36. K. Anwar, K. Nakakuki, T. Shiraishi, H. Naiki, R. Yatani and M. Inuzuka, Presence of ras oncogene mutations and human papillomavirus DNA in human prostate carcinomas. Cancer Res. 52, 5991-5996 (1992).
37. G. Riou, M. Barrois, Z. M. Sheng, P. Duvillard and C. Lhomme, Somatic deletions and mutations of c-Ha-nis gene in human cervical cancers. Oncogene 3, 329-333 (1988).
38. R. H. Hruban, A. D. van Mansfeld, G. J. Offerhaus, D. H. van Weering, D. C. Allison, S. N. Goodman, T. W. Kensler, K. K. Bose, J. L. Cameron and J. L. Bos, K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am. J. Pathol. 143, 545-554 (1993).
39. B. Vogelstein, E. R. Fearon, S. R. Hamilton, S. E. Kern, A. C. Preisinger, M. Leppert, Y. Nakamura, R. White, A. M. M. Smits and J. L. Bos, Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 319, 525-532 (1988).
40. W. H. Westra, R. J. Slebos, G. J. Offerhaus, S. N. Goodman, S. G. Evers, T. W. Kensler, F. B. Askin, S. Rodenhuis and R. H. Hruban, K-ras oncogene activation in lung adenocarcinomas from former smokers. Evidence that K-ras mutations are an early and irreversible event in the development of adenocarcinoma of the lung. Cancer 72, 432-438 (1993).
41. N. E. Mills, C. L. Fishman, W. N. Rom, N. Dubin and D. R. Jacobson, Increased prevalence of K-ras oncogene mutations in lung adenocarcinoma. Cancer Res. 55, 1444-1447 (1995).
42. G. G. Steel, Cellular sensitivity to low dose-rate irradiation focuses the problem of tumour radioresistance. Radiother. Oncol. 20, 71-83 (1991).
43. H. D. Thames, T. E. Schultheiss, J. H. Hendry, S. L. Tucker, B. M. Dubray and W. A. Brock, Can modest escalations of dose be detected as increased tumor control? Int. J. Radiat. Oncol. 22, 241-246 (1992).
44. J. Nemunaitis, J. Cox, W. Meyer, A. Courtney and G. Mues, Irinotecan hydrochloride (CPT-11) resistance identified by K-ras mutation in patients with progressive colon cancer after treatment with 5-fluorouracil (5-FU). Am. J. Clin. Oncol. 20, 527-529 (1997).
45. R. Rosell, J. L. Gonzalez-Larriba, V. Alberola, F. Molina, M. Monzo, D. Benito, J. M. Perez and J. M. de Anta, Single-agent paclitaxel by 3-hour infusion in the treatment of non-small cell lung cancer: Links between p53 and K-ras gene status and chemosensitivity. Semin. Oncol. 22, 12-18 (1995).
46. J. Sun, M. A. Blaskovich, D. Knowles, Y. Qian, J. Ohkanda, R. D. Bailey, A. D. Hamilton and S. M. Sebti, Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine. Cancer Res. 59, 4919-4926 (1999).